Medivir AB (MVIRb.ST)
22 Aug 2014
|Market Cap (Mil.):||kr3,863.25|
|Shares Outstanding (Mil.):||30.60|
Aug 21 - Medivir : * Q2 - net turnover totalled SEK 564.0 million (40.7) * Q2 profit after tax was SEK 327.8 million (-63.7) Link to press release: http://mb.cision.com/Main/652/9631260/277089.pdf
Aug 4 - Medivir : * Licenses respiratory syncytial virus drug program from boehringer ingelheim * Medivir today announces that it has entered a license agreement with Boehringer Ingelheim International GmbH for exclusive, global rights to a drug program for the treatment and prevention of Respiratory Syncytial Virus (RSV) infection. * Under the terms of the agreement Medivir receives an exclusive, global license to research, develop, manufacture and commercialise RSV drugs resulting
July 28 - Medivir : * Phase II cosmos study results published in the lancet on world hepatitis day * Says 92 percent of genotype 1 chronic hepatitis c virus adult patients
Earnings vs. Estimates
Analyst Research Reports
Provider: Wright Reports
Medivir AB: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
Provider: Thomson Reuters StreetEvents
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.